As part of a customer-focused initiative to unite its diverse fine chemicals capabilities, Johnson Matthey, a US company best known internationally for catalyst manufacture, has realigned the business, creating four key platforms: Custom Pharma Solutions, Controlled Substances, Catalysts and APIs & Life Cycle Management.

The company said the new branding brings together its broad chiral and catalysis technologies with “world-leading” opiates and narcotics capabilities, as well as its global API development, life cycle management and manufacturing expertise.

The realignment will enhance access for customers to the company’s complex chemistry capabilities and differentiating technologies,” said John Fowler, division director at Johnson Matthey Fine Chemicals.

The initiative, Fowler said, is aimed at enhancing collaborative working across Johnson Matthey ten global fine chemicals sites, thereby enabling greater advances in product development and creating additional value for customer projects.